December 1, 2024
Therapy Articles
December 1, 2024
Pharmacologic Agents for Refractive Correction
By Richard L. Lindstrom, MD
August 12, 2024
LENZ Therapeutics Submits NDA for Presbyopia Treatment
March 1, 2024
Getting “Close”-er
By Jacob Lang, OD, Jennifer Loh, MD
December 1, 2023
Taking a Closer Look at QLOSI
By Jacob Lang, OD, Jade Coats, OD
December 1, 2023
Vuity Eye Drops: Personalized Vision Enhancement
By ELISE KRAMER, OD, FAAO
December 1, 2023
Ocular Surface and Lid Margin Optimization Prior to Refractive Cataract Surgery
By Caroline Watson, MD
September 1, 2023
Differentiating Miotics for Pharmacological Management of Presbyopia
By S. BARRY EIDEN, OD, FAAO, Marc Odrich, MD
June 1, 2023
Brimochol PF Meets Near Vision Endpoints
By Eric D. Donnenfeld, M.D., F.A.C.S.
June 1, 2023
Vuity Reimagined: FDA Approval for BID Dosing
By Cecelia Koetting, OD, FAAO
June 1, 2023
Shrinking Night Vision Disturbances
By JUSTIN SCHWEITZER, OD, FAAO
March 1, 2023
Another Year Older and Wiser
By Jade Coats, OD
March 1, 2023
Prescribing Presbyopia-Correcting Solutions: Getting Into the Groove
By Rachael Wruble, OD
March 1, 2023
Presbyopia Drops: Patient Selection and the X Factor
By MILTON HOM, O.D., F.A.A.O.
December 1, 2022
Treatment of Presbyopia: One of Several Potential Indications for Nyxol
By Jay S. Pepose, MD, PhD
December 1, 2022
INDUSTRY BRIEFS
By Andrew E. Mathis, PhD, contributing writer
December 1, 2022
CATCH PHRASE
September 1, 2022
Adjusting to the Realities of Vuity
By Richard L. Lindstrom, MD
September 1, 2022
Capturing First-time Patients With Vuity
By Marjan Farid, MD
September 1, 2022
What Are Some of My Vuity Success Stories?
By Vin Dang, OD
September 1, 2022
New for the Presbyope: Pharmacologic Options
By KATHRYN HATCH, MD
September 1, 2022
Evaluating Vuity From the Vitreoretinal Specialist's Perspective
By Ehsan Rahimy, MD, Suzanne Michalak, MD
September 1, 2022
Distinguishing Between Upcoming Pharmacologic Treatments
By Steve Lenier
March 1, 2022
The Presbyopia Disconnect
By SELINA R. MCGEE, OD, FAAO